GlassScriptPhysician profile
Olga Ulitsky
NPI 1023284536
$9,447.05
in general payments reported to CMS, 2019-2025
30 companies · $1,324 in 2025
The $1,324 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,244 · 2020: $791 · 2021: $1,249 · 2022: $1,199 · 2023: $1,955 · 2024: $1,685 · 2025: $1,324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,856 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,856.00 |
| Education | $108.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $1,003.83 | 2019-2025 | Blu-U |
| Arcutis Biotherapeutics, INC. | $863.63 | 2023-2024 | Zoryve |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $706.32 | 2019-2023 | Siliq |
| Abbvie INC. | $688.88 | 2020-2025 | Rinvoq, Skyrizi |
| Novartis Pharmaceuticals Corporation | $670.92 | 2019-2025 | |
| Galderma Laboratories, L.P. | $596.03 | 2019-2025 | Nemluvio, Aklief, Oracea |
| Janssen Biotech, INC. | $591.24 | 2019-2024 | Tremfya, Remicade, Stelara |
| Lilly USA, LLC | $529.04 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Pfizer INC. | $522.86 | 2019-2023 | |
| Ucb, INC. | $439.98 | 2021-2025 | Bimzelx |
| Amgen INC. | $365.52 | 2020-2025 | Otezla, Otezla |
| Merz North America, INC. | $359.95 | 2021-2025 | |
| Allergan, INC. | $350.94 | 2019-2022 | |
| Epi Health, LLC | $312.83 | 2019-2022 | |
| Leo Pharma INC. | $216.73 | 2019-2023 | Adbry |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $181.03 | 2019-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $176.25 | 2022-2025 | Spevigo |
| Incyte Corporation | $169.95 | 2022-2024 | Opzelura |
| Vyne Pharmaceuticals INC. | $158.81 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $90.76 | 2023-2025 | Sotyktu |
| Revance Therapeutics, INC. | $86.41 | 2024-2025 | Daxxify |
| Organogenesis INC. | $76.96 | 2025 | Via Matrix, Puraply Wound Matrix |
| Almirall LLC | $72.38 | 2019-2024 | Seysara |
| Genzyme Corporation | $62.62 | 2019-2020 | |
| Dermavant Sciences, INC. | $40.25 | 2023 | Vtama |
| Dermira, INC. | $30.50 | 2019 | |
| Kerecis Limited | $26.52 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Dusa Pharmaceuticals, INC. | $23.49 | 2019 | |
| Strata Skin Sciences, INC. | $18.69 | 2025 | Xtrac |
| Nabriva Therapeutics, Plc | $13.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Olga Ulitsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.